THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

[Claim 1]

An siRNA having a full length of 23 or fewer nucleotides which is selected from the following (a) to (j):

(a) an siRNA comprising a sense sequence of SEQ ID NO: 2 and an antisense sequence of SEQ ID NO: 3;

(b) an siRNA comprising a sense sequence of SEQ ID NO: 10 and an antisense sequence of SEQ ID NO: 11;

(c) an siRNA comprising a sense sequence of SEQ ID NO: 16 and an antisense sequence of SEQ ID NO: 17;

(d) an siRNA comprising a sense sequence of SEQ ID NO: 18 and an antisense sequence of SEQ ID NO: 19;

(e) an siRNA comprising a sense sequence of SEQ ID NO: 20 and an antisense sequence of SEQ ID NO: 21;

(f) an siRNA comprising a sense sequence of SEQ ID NO: 22 and an antisense sequence of SEQ ID NO: 23;

(g) an siRNA comprising a sense sequence of SEQ ID NO: 24 and an antisense sequence of SEQ ID NO: 25;

(h) an siRNA comprising a sense sequence of SEQ ID NO: 28 and an antisense sequence of SEQ ID NO: 29;

(i) an siRNA comprising a sense sequence of SEQ ID NO: 30 and an antisense sequence of SEQ ID NO: 31; and

(j) an siRNA comprising a sense sequence of SEQ ID NO: 54 and an antisense sequence of SEQ ID NO: 55.

[Claim 2]

The siRNA according to claim 1, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3' terminus of the sense strand of the siRNA are converted into DNA.

[Claim 3]

The siRNA according to claim 1 or 2, wherein 1 to 10 consecutive nucleotides from the 5' terminus of the antisense strand of the siRNA are converted into DNA.

[Claim 4]

The siRNA according to any one of claims 1 to 3, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3' terminus of the sense strand of the siRNA are converted into DNA and 1 to 10 consecutive nucleotides from the 5' terminus of the antisense strand of the siRNA are converted into DNA.

[Claim 5]

The siRNA according to any one of claims 1 to 4, wherein the 5' terminus of the antisense strand is monophosphorylated or monothiophosphorylated.

[Claim 6]

A pharmaceutical composition comprising the siRNA according to any one of claims 1 to 5.

[Claim 7]

A TGF-β1 gene expression inhibitor comprising the siRNA according to any one of claims 1 to 5 as an active ingredient.

[Claim 8]

A preventive or therapeutic agent for fibrosis comprising the siRNA according to any one of claims 1 to 5 as an active ingredient.

[Claim 9]

A preventive or therapeutic agent for pulmonary fibrosis or lung cancer comprising the siRNA according to any one of claims 1 to 5 as an active ingredient.

[Claim 10]

Use of the siRNA according to any one of claims 1 to 5 for the production of a TGF-β1 gene expression inhibitor.

[Claim 11]

Use of the siRNA according to any one of claims 1 to 5 for the production of a preventive or therapeutic agent for fibrosis.

[Claim 12]

Use of the siRNA according to any one of claims 1 to 5 for the production of a preventive or therapeutic agent for pulmonary fibrosis or lung cancer.

[Claim 13]

The siRNA according to any one of claims 1 to 5 for use in inhibiting TGF-β1 gene expression.

[Claim 14]

The siRNA according to any one of claims 1 to 5 for use in preventing or treating fibrosis.

[Claim 15]

The siRNA according to any one of claims 1 to 5 for use in preventing or treating pulmonary fibrosis or lung cancer.